Before you can access ASH's online program, you must agree to the following:
Last updated January 16, 2009. Please note that this site represents the latest program changes
and differs from the print version in some details.

622.O2.6 Diffuse Large B-cell Lymphoma: Biology and Prognosis

Monday, December 8, 2008: 1:30 PM-3:00 PM
3001-3003-3005 - West (Moscone Center)
Moderators:
Yasodha Natkunam and Wing C. Chan
1:30 PM
Molecular Signatures Implicate Innate Immune Cells, Fibrosis, and Angiogenesis in Survival Following R-CHOP Treatment of Diffuse Large B Cell Lymphoma

Georg Lenz1*, George Wright, Ph.D.2*, Sandeep Dave3, Wenming Xiao4*, John Powell4*, Hong Zhao4*, Weihong Xu4*, Bruce Tan4*, Neta Goldschmidt4*, Javeed Iqbal, Ph.D.5*, Julie Vose4*, Martin A Bast4*, Kai Fu4*, Dennis D. Weisenburger4*, Timothy C. Greiner4*, James O. Armitage4*, Alastair Kyle4*, Lorraine May4*, Randy D. Gascoyne4*, Joseph M. Connors4*, Gunhild Troen4*, Harald Holte4*, Stein Kvaloy4*, Daan Dierickx4*, Gregor Verhoef4*, Jan Delabie6*, Erlend B. Smeland4*, Pedro Jares4*, Antonio Martinez7*, Armando Lopez-Guillermo4, Emili Montserrat4, Elias Campo4*, Rita M. Braziel4, Thomas P. Miller4*, Lisa M. Rimsza4, James R. Cook4*, Brad Pohlman, MD4, John William Sweetenham4, Raymond R. Tubbs4, Richard I. Fisher4*, Elena Hartmann4*, Andreas Rosenwald4*, German Ott4*, Hans-Konrad Muller-Hermelink4*, David Wrench4*, T. Andrew Lister8, Elaine S. Jaffe4, Wyndham Wilson4, Wing C. Chan5 and Louis M. Staudt, MD., Ph.D.2

1LLMPP, Bethesda, MD
2Metabolism Branch, Center for Cancer Research, National Cancer Institute, National Health Institutes, Bethesda, MD
3Duke University, Durham, NC
4LLMPP
5Pathology and Microbiology, University of Nebraska Medical Center, Omaha, NE
6Pathology, Norwegian Radium Hospital, Oslo, Norway
7Hospital Clinic, Barcelona, Spain
8Centre for Medical Oncology, Barts and the London School of Medicine and Dentistry, London, United Kingdom

1:45 PM
Biologic Prognostic Markers in Diffuse Large B-Cell Lymphoma Patients Treated with Dose Adjusted EPOCH-R:  a CALGB 50103 Correlative Science Study

Eric D Hsi, MD1, Jonathan Said2*, Jeffrey L Johnson3*, Sinho Jung3*, Raymond Lai, MD4*, Dan Jones, MD, PhD5, Amy Chadburn, MD6, Bruce D. Cheson, MD7 and Wyndham H. Wilson8*

1Cleveland Clinic, Cleveland, OH
2UCLA Medical Center, Los Angeles, CA
3CALGB Statistical Office, Duke University Medical Center, Durham, NC
4Cross Cancer Center, Edmonton, AB, Canada
5Dept. of Hematopathology, UT M.D. Anderson Cancer Ctr., Houston, TX
6Cornell Campus, New York Presbyterian Hospital, New York, NY
7Lombardi Cancer Ctr., Georgetown Univ. Hosp., Washington, DC
8CBER, FDA, Bethesda, MD

2:00 PM
Deletion in Chromosome 17p12 and Gains in Chromosome 9q33.3 by Array Comparative Hybridization Are Associated with R-CHOP Treatment Failure in Patients with Diffuse Large B Cell Lymphoma

Nathalie Johnson, MD1*, Ronald J De Leeuw2*, Julia Chae2*, Sohrab P Shah1*, Wan L Lam2*, Thomas Relander3*, Joseph M. Connors, MD4, Douglas E. Horsman, MD1* and Randy D. Gascoyne, MD1*

1Pathology and Laboratory Medicine, British Columbia Cancer Agency, Vancouver, BC, Canada
2Cancer Genetics and Developmental Biology, British Columbia Cancer Research Center, BC, Canada
3Oncology, Lund University Hospital, Lund, Sweden
4Medical Oncology, British Columbia Cancer Agency, Vancouver, BC, Canada

2:15 PM
Array-CGH Identifies Regions, Including the FOXP1 Locus, Associated with Different Clinical Outcome in Diffuse Large B-Cell Lymphomas (DLBCL) Treated with R-CHOP

Marta Scandurra1*, Paola M.V. Rancoita1*, Timothy C. Greiner2*, Wing C. Chan2, Julie M. Vose, MD2, Giorgio Inghirami3*, Annalisa Chiappella3*, Luca Baldini, MD4*, Maurilio Ponzoni5*, Andres JM Ferreri, MD6, Santiago Montes-Moreno7*, Miguel A. Piris7*, Silvia Franceschetti8*, Gianluca Gaidano8*, Fabio Facchetti9*, Alessandra Tucci9*, Thierry Lazure10*, Olivier Lambotte10*, Silvia Uccella11*, Graziella Pinotti12*, Giancarlo Pruneri13*, Giovanni Martinelli14, Josep Nomdedeu15*, Maria Grazia Tibiletti11*, Ekaterina Chigrinova1*, Cassio P. De Campos1*, Andrea Rinaldi1*, Emanuele Zucca1*, Ivo Kwee1* and Francesco Bertoni, MD1

1Laboratory of Experimental Oncology and Lymphoma Unit, Oncology Institute of Southern Switzerland (IOSI), Bellinzona, Switzerland
2UNMC, Omaha, NE
3University of Torino and Ospedale Maggiore San Giovanni Battista, Torino, Italy
4Department of Medical Science - O.U. Hematology 1, University of Milan - Fondazione IRCCS Policlinico, Milan, Italy
5HSR, Milan, Italy
6Unit of Lymphoid Malignancies, Department of Oncology, Istituto Scientifico San Raffaele, Milano, Italy
7CNIO, Madrid, Spain
8Division of Hematology, Department of Clinical and Experimental Medicine, Amedeo Avogadro University of Eastern Piedmont, Novara, Italy
9Spedali Civili, Brescia, Italy
10Bicêtre Hospital, Paris, France
11Insubria University, Varese, Italy
12UO Oncologia Medica, Ospedale di Circolo Fondazione Macchi, Varese
13Anatomy and Pathology, European Institute of Oncology, Milan, Italy
14Hematology, European Institute of Oncology, Milan, Italy
15Department of Hematology, Hospital Sant Pau, Barcelona, Spain

2:30 PM
Expression of Hypoxia-Inducible Factor (HIF) Is An Independent Favorable Prognostic Factor in Diffuse Large B-Cell Lymphoma (DLBCL) Treated with R-CHOP

Andrew M. Evens, DO, MS1, Laurie H. Sehn, MD, MPH2*, Pedro Farinha, MD3*, Paul T Schumacker, PhD4*, Adekunle Raji, MS1*, Yi Lu, MD1*, Beverly P. Nelson, MD1*, Randy D. Gascoyne, MD3* and Leo I. Gordon, MD1*

1Hematology/Oncology, The Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL
2Department of Medicine, British Columbia Cancer Agency (BCCA), Vancouver, BC, Canada
3Department of Pathology, British Columbia Cancer Agency (BCCA), Vancouver, BC, Canada
4Department of Pediatrics, The Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL

2:45 PM
The Pharmacogenetic Background of the Host Is An Independent Predictor of Outcome and Toxicity in Diffuse Large B Cell Lymphoma Treated with R-CHOP21

Davide Rossi1, Silvia Rasi1*, Silvia Franceschetti1*, Daniela Capello1*, Andrea Castelli1*, Lorenzo De Paoli1*, Antonio Ramponi1*, Annalisa Chiappella2*, Enrico M. Pogliani3*, Umberto Vitolo2*, Ivo Kwee4*, Francesco Bertoni4*, Annarita Conconi1* and Gianluca Gaidano1

1Hematology, Amedeo Avogadro University of Eastern Piedmont, Novara, Italy
2Hematology, AOU San Giovanni Battista, Torino, Italy
3Hematology, University of Milano Bicocca
4Laboratory of Experimental Oncology, Oncology Institute of Southern Switzerland (IOSI)

*signifies non-member of ASH